Prestige Takes Trastuzumab A Step Closer To US Filing
As Major Shareholder Invests Further In Singapore-Based Biosimilars Developer
Prestige says a meeting with the FDA in November represents a “final step” before filing its trastuzumab biosimilar with the US agency by the end of the year. Meanwhile, a major shareholder has invested further in the Singapore-based biosimilars developer.
